- Home
- CTMX vs DFP Comparison
CTMX vs DFP Comparison
Compare CTMX & DFP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTMX
- DFP
- Stock Information
- Founded
- CTMX 2008
- DFP 2013
- Country
- CTMX United States
- DFP United States
- Employees
- CTMX N/A
- DFP N/A
- Industry
- CTMX Biotechnology: Pharmaceutical Preparations
- DFP Investment Managers
- Sector
- CTMX Health Care
- DFP Finance
- Exchange
- CTMX Nasdaq
- DFP Nasdaq
- Market Cap
- CTMX 444.3M
- DFP 417.1M
- IPO Year
- CTMX 2015
- DFP N/A
- Fundamental
- Price
- CTMX $2.48
- DFP $20.73
- Analyst Decision
- CTMX Strong Buy
- DFP
- Analyst Count
- CTMX 2
- DFP 0
- Target Price
- CTMX $5.00
- DFP N/A
- AVG Volume (30 Days)
- CTMX 2.7M
- DFP 56.2K
- Earning Date
- CTMX 08-07-2025
- DFP 01-01-0001
- Dividend Yield
- CTMX N/A
- DFP 6.73%
- EPS Growth
- CTMX 128.27
- DFP N/A
- EPS
- CTMX 0.49
- DFP N/A
- Revenue
- CTMX $147,557,000.00
- DFP N/A
- Revenue This Year
- CTMX N/A
- DFP N/A
- Revenue Next Year
- CTMX N/A
- DFP N/A
- P/E Ratio
- CTMX $5.11
- DFP N/A
- Revenue Growth
- CTMX 23.81
- DFP N/A
- 52 Week Low
- CTMX $0.40
- DFP $15.45
- 52 Week High
- CTMX $3.10
- DFP $19.31
- Technical
- Relative Strength Index (RSI)
- CTMX 56.59
- DFP 73.91
- Support Level
- CTMX $2.15
- DFP $20.36
- Resistance Level
- CTMX $2.44
- DFP $20.43
- Average True Range (ATR)
- CTMX 0.24
- DFP 0.15
- MACD
- CTMX -0.05
- DFP 0.03
- Stochastic Oscillator
- CTMX 39.71
- DFP 95.86
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
About DFP Flaherty & Crumrine Dynamic Preferred and Income Fund Inc.
Flaherty & Crumrine Dynamic Preferred and Income Fund Inc is a diversified, closed-end management investment company. Its investment objective is to seek total return, with an emphasis on high current income.